BOSTON – Reports of possible allergic reactions to the COVID-19 vaccines produced by Pfizer-BioNTech and Moderna, both recently approved for emergency use by the U.S. Food and Drug Administration (FDA), have raised public concern. A team of experts led by allergists at Massachusetts General Hospital (MGH) has now examined all relevant information to offer reassurance that the vaccines can be administered safely even to people with food or medication allergies. The group’s review is published in the Journal of Allergy and Clinical Immunology: In Practice.
In response to accounts of potential allergic reactions in some people following COVID-19 vaccination in the United Kingdom, that country’s medical regulatory agency advised that individuals with a history of anaphylaxis to a medicine or food should avoid COVID-19 vaccination. After closer review of the data related to allergic reactions, however, the FDA recommended that the vaccines be withheld only from individuals with a history of severe allergic reactions to any component of the COVID-19 vaccine, and the Centers for Disease Control and Prevention advised that all patients be observed for 15 minutes post-vaccination by staff who can identify and manage such reactions. The U.S. agencies do not recommend that people with food or medication allergies avoid vaccination.
Continue reading “Allergists offer reassurance regarding potential allergic reactions to COVID-19 vaccines”
Australian researchers have revealed – for the first time – that people who have been infected with the COVID-19 virus have immune memory to protect against reinfection for at least eight months.
The research is the strongest evidence for the likelihood that vaccines against the virus, SARS-CoV-2, will work for long periods. Previously, many studies have shown that the first wave of antibodies to coronavirus wane after the first few months, raising concerns that people may lose immunity quickly. This new work allays these concerns.
The study is the result of a multi-centre collaboration led by Associate Professor Menno van Zelm, from the Monash University Department of Immunology and Pathology, with the Alfred Research Alliance between Monash University, The Alfred hospital and the Burnet Institute, and published today in the prestigious journal, Science Immunology. The publication reveals the discovery that specific cells within the immune system called memory B cells, “remembers” infection by the virus, and if challenged again, through re-exposure to the virus, triggers a protective immune response through rapid production of protective antibodies.
Continue reading “Long-lasting COVID immunity gives real hope for the long-term protection of vaccines”
Calculator generates mortality risk estimates for individuals and communities based on sociodemographic info and medical history
A new online calculator for estimating individual and community-level risk of dying from COVID-19 has been developed by researchers at the Johns Hopkins Bloomberg School of Public Health. The researchers who developed the calculator expect it to be useful to public health authorities for assessing mortality risks in different communities, and for prioritizing certain groups for vaccination as COVID-19 vaccines become available.
The algorithm underlying the calculator uses information from existing large studies to estimate risk of COVID-19 mortality for individuals based on age, gender, sociodemographic factors and a variety of different health conditions. The risk estimates apply to individuals in the general population who are currently uninfected, and captures factors associated with both risk of future infection and complications after infection.
Continue reading “New online COVID-19 mortality risk calculator could help determine who should get vaccines first”